QCM
CRSP icon

Quantinno Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Quantinno Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87M Buy
52,610
+4,621
+10% +$244K ﹤0.01% 1663
2026
Q1 		$2.28M Buy
47,989
+41,263
+613% +$2.18M ﹤0.01% 1532
2025
Q4 		$353K Buy
6,726
+2,005
+42% +$120K ﹤0.01% 2722
2025
Q3 		$306K Buy
+4,721
New +$271K ﹤0.01% 2437

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quantinno Capital Management's CRSP Position: Q2 2026 in Review

Quantinno Capital Management increased its CRISPR Therapeutics (CRSP) stake by 9.6% in Q2 2026, buying an estimated $244K and bringing the position to 52,610 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1663.

Quantinno Capital Management first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Quantinno Capital Management held 52,610 shares of CRISPR Therapeutics worth $2.87M as of Q2 2026.
  • Quantinno Capital Management bought 4,621 CRISPR Therapeutics shares in Q2 2026, an estimated $244K.
  • CRISPR Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #1663 holding.
  • Quantinno Capital Management first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.